Advertisement
Screener

AEON Biopharma, Inc. (AEON) Debt Conversion, Converted Instrument, Amount

2.8 / 5 stars · 68/120 Roast Me

AEON Biopharma, Inc. Debt Conversion, Converted Instrument, Amount

AEON Biopharma, Inc. (AEON) reported Debt Conversion, Converted Instrument, Amount of $31.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Financing Activities

us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2026-08-12

  • AEON Biopharma, Inc. debt conversion, converted instrument, amount for the quarter ending 2026-06-30 was $0.00.
  • AEON Biopharma, Inc. debt conversion, converted instrument, amount for the quarter ending 2026-03-31 was $31.49M.
Period endDebt Conversion, Converted Instrument, Amount 3 monthDebt Conversion, Converted Instrument, Amount 6 month
2026-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
$31.49M
10-Q · filed 2026-08-12
2026-03-31$31.49M
10-Q · filed 2026-05-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
MUSTANG BIO, INC. (MBIO)United States$0.013B
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
Tempest Therapeutics, Inc. (TPST)United States$0.013B
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
BIOVIE INC. (BIVI)United States$0.012B
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
Vyome Holdings, Inc (HIND)United States$0.014B-1.38